TY - JOUR
T1 - Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate
AU - Meyer, W. J.
AU - Walker, P. A.
AU - Emory, L. E.
AU - Smith, E. R.
N1 - Funding Information:
Received March 6, 1984; revised and accepted September 10, 1984. *Supported by the Department of Pediatrics, University of Texas Medical Branch; The Hogg Foundation; The Upjohn Company; and grant RR73 from the Clinical Research Center Program of the Division of Research Resource, National Institutes of Health, Public Health Service. tDepartment of Pediatrics. +Reprint requests: Walter J. Meyer III, M.D., The University of Texas Medical Branch, Department of Pediatrics, CHC C-63, Galveston, Texas 77550-2776. §Department of Psychiatry and Behavioral Science. IIPresent address: San Francisco, California. ~Department of Obstetrics and Gynecology.
PY - 1985
Y1 - 1985
N2 - Twenty-three men were treated with injectable medroxyprogesterone acetate (MPA) for sex-offending behavior. The physical, hormonal, and metabolic effects were monitored. The patients had significant (P < 0.001) weight gain and increases (P < 0.0001) in systolic blood pressure independent of weight gain, MPA therapy decreased testosterone (P < 0.0001), luteinizing hormone (P < 0.005), and testicular size (P < 0.001), but not follicle-stimulating hormone, MPA's suppression of total sperm count was not consistent, but MPA significantly reduced sperm motility (P < 0.001) and percent normal morphology (P < 0.005). Statistically insignificant increases in insulin response without changes in glucose tolerance occurred in all patients, but only one patient developed overt diabetes mellitus. Three men developed gallstones, but none had significant changes in liver function. Patients receiving high-dose MPA therapy should be carefully monitored for blood pressure changes, diabetes mellitus, and gallbladder dysfunction.
AB - Twenty-three men were treated with injectable medroxyprogesterone acetate (MPA) for sex-offending behavior. The physical, hormonal, and metabolic effects were monitored. The patients had significant (P < 0.001) weight gain and increases (P < 0.0001) in systolic blood pressure independent of weight gain, MPA therapy decreased testosterone (P < 0.0001), luteinizing hormone (P < 0.005), and testicular size (P < 0.001), but not follicle-stimulating hormone, MPA's suppression of total sperm count was not consistent, but MPA significantly reduced sperm motility (P < 0.001) and percent normal morphology (P < 0.005). Statistically insignificant increases in insulin response without changes in glucose tolerance occurred in all patients, but only one patient developed overt diabetes mellitus. Three men developed gallstones, but none had significant changes in liver function. Patients receiving high-dose MPA therapy should be carefully monitored for blood pressure changes, diabetes mellitus, and gallbladder dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=0021961212&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021961212&partnerID=8YFLogxK
U2 - 10.1016/s0015-0282(16)48326-3
DO - 10.1016/s0015-0282(16)48326-3
M3 - Article
C2 - 3155506
AN - SCOPUS:0021961212
SN - 0015-0282
VL - 43
SP - 102
EP - 109
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 1
ER -